Compare WAY & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WAY | GH |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 13.3B |
| IPO Year | 2023 | 2018 |
| Metric | WAY | GH |
|---|---|---|
| Price | $24.86 | $88.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 20 |
| Target Price | $37.56 | ★ $117.80 |
| AVG Volume (30 Days) | ★ 2.6M | 1.6M |
| Earning Date | 05-20-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 569.23 | 6.74 |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $1,099,278,000.00 | $982,021,000.00 |
| Revenue This Year | $18.35 | $33.40 |
| Revenue Next Year | $10.53 | $28.55 |
| P/E Ratio | $40.66 | ★ N/A |
| Revenue Growth | 16.50 | ★ 32.88 |
| 52 Week Low | $21.13 | $36.36 |
| 52 Week High | $41.96 | $120.74 |
| Indicator | WAY | GH |
|---|---|---|
| Relative Strength Index (RSI) | 44.83 | 38.42 |
| Support Level | $21.13 | $54.39 |
| Resistance Level | $26.29 | $103.16 |
| Average True Range (ATR) | 1.08 | 3.90 |
| MACD | 0.02 | -0.28 |
| Stochastic Oscillator | 25.24 | 39.48 |
Waystar Holding Corp is a provider of mission-critical cloud technology to healthcare organizations. Its enterprise-grade platform transforms the complex and disparate processes comprising healthcare payments received by healthcare providers from payers and patients, from pre-service engagement through post-service remittance and reconciliation. its platform enhances data integrity, eliminates manual tasks, and improves claim and billing accuracy, which results in transparency, reduced labor costs, and faster, more accurate reimbursement and cash flow. The market for solutions extends throughout the United States and includes Puerto Rico and other USA Territories.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.